The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes
Abstract
To determine the usefulness of [18F]fluorodeoxyglucose (FDG) whole body FDG-PET in the diagnosis of tumours in patients with paraneoplastic neurological syndromes (PNS), we prospectively studied 20 patients with paraneoplastic antibodies in whom conventional imaging gave negative or inconclusive results for the presence of tumour. All 20 patients had neurological manifestations compatible with PNS and well-characterized paraneoplastic antibodies (12 anti-Hu, one anti-Hu and anti-CV2, one anti-CV2, four anti-Yo, one anti-Ri and one anti-amphiphysin). The mean delay between the onset of neurological symptoms and FDG-PET was 10 months (range 1-54). In these 20 patients, abnormal uptake was demonstrated in 18 patients, with some patients having abnormal signal in several areas. We observed abnormal uptake in the mediastinum (13 cases), lung (two cases), breast (two cases), parotid gland (one case), or the cervical, supraclavicular or axillary lymph nodes (seven cases). Following FDG-PET, the histological diagnosis of the tumour was made in 14 patients (small cell lung carcinoma in eight cases, breast adenocarcinoma in two, lung adenocarcinoma in two, axillary metastasis of ovary carcinoma in one, and malignant thymoma in one). Two other patients with abnormal FDG uptake showed radiological evidence of lung cancer, but a histological diagnosis could not be obtained. In two other patients, initial FDG-PET showed abnormal FDG uptake that was not confirmed a few months later by repeat FDG-PET. In the two patients with negative FDG-PET, peritoneal carcinomatosis was diagnosed in one and no tumour was found in the other. In our series, the sensitivity of FDG-PET for tumour detection was >83% demonstrating a clear role of this technique in the management of patients with PNS. However, in our series, the specificity of FDG uptake was only 25% due to unexplained abnormal FDG uptake in three patients and in abnormal FDG uptake due to a benign tumour in one patient. Over the study period, we saw 73 other patients with PNS and paraneoplastic antibodies. A tumour was demonstrated in 71 out of 73 by conventional techniques. Since false-positive and false-negative results are possible with FDG-PET and in most patients with PNS, the tumour is demonstrated by conventional techniques, we believe that FDG-PET should be reserved, at the moment, for patients with well-defined PNS antibodies when conventional imaging fails to identify a tumour or when lesions are difficult to biopsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lucchinetti, C. F., Kimmel, D. W., & Lennon, V. A. (1998) · Neurology · doi:10.1212/wnl.50.3.652 · Cited by 499
Cited by
Paraneoplastic syndromes of the CNS
Dalmau, J., & Rosenfeld, M. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70060-7 · Cited by 873
Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force
Titulaer, M. J., Soffietti, R., Dalmau, J., Gilhus, N. E., Giometto, B., Graus, F., Grisold, W., Honnorat, J., Sillevis Smitt, P. A. E., Tanasescu, R., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03220.x · Cited by 526
Paraneoplastic neurological syndromes
Honnorat, J., & Antoine, J.-C. (2007) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-2-22 · Cited by 357
Autoimmune Encephalitis: Pathophysiology and Imaging Review of an Overlooked Diagnosis
Kelley, B. P., Patel, S. C., Marin, H. L., Corrigan, J. J., Mitsias, P. D., & Griffith, B. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5086 · Cited by 310
Metadata
- Authors
- Younes-Mhenni, S.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-09-13
- Volume
- 127
- Issue
- 10
- Pages
- 2331-2338
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2118548688
- Cited by
- 237
- References
- 1
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. https://app.cochat.ai/papers/10.1093/brain/awh247
- The paper
- Younes-Mhenni, S. (2004). FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain. https://doi.org/10.1093/brain/awh247
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.